Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Assets: 2017-2025

Historic Assets for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $1.1 billion.

  • Denali Therapeutics' Assets fell 27.40% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 27.40%. This contributed to the annual value of $1.4 billion for FY2024, which is 19.09% up from last year.
  • Per Denali Therapeutics' latest filing, its Assets stood at $1.1 billion for Q3 2025, which was down 9.49% from $1.2 billion recorded in Q2 2025.
  • Denali Therapeutics' Assets' 5-year high stood at $1.6 billion during Q1 2024, with a 5-year trough of $1.1 billion in Q3 2025.
  • For the 3-year period, Denali Therapeutics' Assets averaged around $1.3 billion, with its median value being $1.3 billion (2023).
  • In the last 5 years, Denali Therapeutics' Assets skyrocketed by 133.23% in 2021 and then decreased by 27.40% in 2025.
  • Quarterly analysis of 5 years shows Denali Therapeutics' Assets stood at $1.4 billion in 2021, then increased by 3.99% to $1.5 billion in 2022, then dropped by 20.98% to $1.2 billion in 2023, then rose by 19.09% to $1.4 billion in 2024, then declined by 27.40% to $1.1 billion in 2025.
  • Its Assets stands at $1.1 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.3 billion for Q1 2025.